[{"uuid": "c0357d12-efa7-4c48-b377-f2bbcb9508dc", "publishTime": "2021-09-21T22:51:19.000Z", "title": "FDA approves Incyte's eczema cream with boxed warnings", "description": "The U.S. Food and Drug Administration on Tuesday approved Incyte Corp's cream Opzelura for treating inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults with boxed warnings.", "assetTags": ["Incyte", "INCY NASDAQ", "INCY US"], "searchTags": ["INCY"], "category": "major_publication", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-incytes-eczema-cream-2021-09-21/?taid=614a802ea5c42200013c6873&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://www.reuters.com/resizer/-aH9oivrs0Zy_FghMBtTP_qfLDM=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/BD5K2CF4GRPRHETPBE3BAELBIU.jpg"], "lang": "en", "cityfalconScore": 60, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 4, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com/news/directory/stocks/incyte-incy"}, {"uuid": "738d9319-b59e-43ce-8732-7fb00b31779f", "publishTime": "2021-10-04T11:14:00.000Z", "title": ": Incyte stock price target cut to $95 from $120 at Truist", "description": "This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.", "assetTags": ["Incyte", "INCY NASDAQ", "INCY US"], "searchTags": ["INCY"], "category": "major_publication", "url": "https://feeds.marketwatch.com/~r/marketwatch/realtimeheadlines/~3/ZNDbVjqbNo0/quotes.asp?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": null, "lang": "en", "cityfalconScore": 47, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com/news/directory/stocks/incyte-incy"}, {"uuid": "3958f07e-15bf-43c7-bd6d-8a690b4f9910", "publishTime": "2021-09-22T12:59:27.000Z", "title": "Incyte gets FDA approval for atopic dermatitis drug", "description": "Shares of Incyte Corp. undefined were down 4.0% in premarket trading on Wednesday, the day after the company announced that the Food and Drug Administration...", "assetTags": ["Incyte", "INCY NASDAQ", "INCY US"], "searchTags": ["INCY"], "category": "major_publication", "url": "https://www.marketwatch.com/story/incyte-gets-fda-approval-for-atopic-dermatitis-drug-2021-09-22?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg"], "lang": "en", "cityfalconScore": 43, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 1, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com/news/directory/stocks/incyte-incy"}, {"uuid": "913498a3-37df-4f45-ba9f-20c5d64ebb91", "publishTime": "2021-09-27T10:24:00.000Z", "title": "Syndax Pharmaceuticals, Incyte Set Global Axatilimab Collaboration >SNDX INCY", "description": "By Colin Kellaher Syndax Pharmaceuticals Inc. and Incyte Corp. on Monday said they signed an exclusive worldwide collaboration and license agreement to...", "assetTags": ["Incyte", "INCY NASDAQ", "INCY US"], "searchTags": ["INCY"], "category": "major_publication", "url": "https://www.marketwatch.com/story/syndax-pharmaceuticals-incyte-set-global-axatilimab-collaboration-sndx-incy-271632738257?reflink=mw_share_twitter&utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"], "lang": "en", "cityfalconScore": 37, "additionalData": {}, "source": {"name": "marketwatch.com", "brandName": "MarketWatch", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/3682/large.png"}}, "duplicatesCount": 0, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com/news/directory/stocks/incyte-incy"}, {"uuid": "66b38350-bded-4886-a8dc-dcd2021d2d16", "publishTime": "2021-09-21T20:16:18.000Z", "title": "FDA approves Incyte's eczema cream", "description": "The U.S. Food and Drug Administration on Tuesday approved Incyte Corp's cream for treating inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults. (Reporting by Bhanvi Satija and Manojna Maddipatla; Editing by Vinay Dwivedi)", "assetTags": ["Incyte", "INCY NASDAQ", "INCY US"], "searchTags": ["INCY"], "category": "major_publication", "url": "https://www.reuters.com/article/incyte-fda-idUSL4N2QN2YY?utm_campaign=cityfalcon&utm_medium=cityfalcon&utm_source=cityfalcon", "imageUrls": ["https://s1.reutersmedia.net/resources_v2/images/rcom-default.png?w=800"], "lang": "en", "cityfalconScore": 35, "additionalData": {}, "source": {"name": "reuters.com", "brandName": "Reuters", "imageUrl": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "imageUrls": {"thumb": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/thumb.png", "small": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/small.png", "medium": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/medium.png", "large": "https://cityfalconproduction.blob.core.windows.net/autotweetmedia/domains/logos/1652606/large.png"}}, "duplicatesCount": 3, "paywall": false, "registrationRequired": false, "cityfalcon_permalink": "https://www.cityfalcon.com/news/directory/stocks/incyte-incy"}]